CYP3A5*3 genotype associated with intrasubject pharmacokinetic variation toward tacrolimus in bioequivalence study

Therapeutic Drug Monitoring

Volumn 32, Issue 1, 2010, Pages 67-72

  Yong Chung, Jae ^a   Jung Lee, Yoon ^a,b   Bok Jang, Seong ^a,b   Ahyoung Lim, Lay ^a,b   Soo Park, Min ^b   Hwan Kim, Kyung ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University   (South Korea)

Author keywords

Bioequivalence; CYP3A5; Intrasubject variation; Pharmacokinetics; Tacrolimus

Indexed keywords

CYTOCHROME P450 3A5; TACROLIMUS; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450 3A; IMMUNOSUPPRESSIVE AGENT;

AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG FORMULATION; DRUG MONITORING; FEMALE; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ASIAN; GENETICS; KOREA; PHARMACOKINETICS;

AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP3A; FEMALE; GENETIC VARIATION; GENOTYPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KOREA; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TACROLIMUS; THERAPEUTIC EQUIVALENCY;

EID: 75749114491     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181c49a4c     Document Type: Article

References (18)

1. Hauschke D, Steinijans WV, Diletti E, et al. Presentation of the intrasubject coefficient of variation for sample size planning in bioequivalence studies. Int J Clin Pharmacol Ther. 1994;32:376-378.
2. Davit BM, Conner DP, Fabian-Fritsch B, et al. Highly variable drugs: observations from bioequivalence data submitted to the FDA for new generic drug applications. AAPS J. 2008;10:148-156.
3. Bekersky I, Dressler D, Colburn W, et al. Bioequivalence of 1 and 5 mg tacrolimus capsules using a replicate study design. J Clin Pharmacol. 1999;39:1032-1037.
4. Lamba JK, Lin YS, Schuetz EG, et al. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev. 2002;54: 1271-1294.
5. Kelly PA, Burckart GJ, Venkataramanan R. Tacrolimus: a new immu-nosuppressive agent. Am J Health Syst Pharm. 1995;52:1521-1535.
6. Roy JN, Barama A, Poirier C, et al. Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients. Pharmacogenet Genomics. 2006;16:659-665.
7. Macphee IA, Fredericks S, Mohamed M, et al. Tacrolimus pharmaco-genetics: the CYP3A5*1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and South Asians. Transplantation. 2005; 79:499-502.
8. Choi JH, Lee YJ, Jang SB, et al. Influence of the CYP3A5 and MDR1 genetic polymorphisms on the pharmacokinetics of tacrolimus in healthy Korean subjects. Br J Clin Pharmacol. 2007;64:185-191.
9. Park K, Kim YS, Kwon KI, et al. A randomized, open-label, two-period, crossover bioavailability study of two oral formulations of tacrolimus in healthy Korean adults. Clin Ther. 2007;29:154-162.
10. Zhang Q, Simpson J, Aboleneen HI. A specific method for the measurement of tacrolimus in human whole blood by liquid chromatog-raphy/tandem mass spectrometry. Ther Drug Monit. 1997;19:470-476.
11. Hauschke D, Steinijans VW, Diletti E, et al. Sample size determination for bioequivalence assessment using a multiplicative model. J Pharmacokinet Biopharm. 1992;20:557-561.
12. Baker SD, van Schaik RH, Rivory LP, et al. Factors affecting cytochrome P-450 3A activity in cancer patients. Clin Cancer Res. 2004;10:8341-8350.
13. Hunt CM, Westerkam WR, Stave GM. Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol. 1992;44:275-283.
14. Ingelman-Sundberg M, Sim SC, Gomez A, et al. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoe-pigenetic and clinical aspects. Pharmacol Ther. 2007;116:496-526.
15. Svecova L, Vrzal R, Burysek L, et al. Azole antimycotics differentially affect rifampicin-induced pregnane X receptor-mediated CYP3A4 gene expression. Drug Metab Dispos. 2008;36:339-348.
16. Floyd MD, Gervasini G, Masica AL, et al. Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European-and African-American men and women. Pharmacogenetics. 2003;13:595-606.
17. Mitchell DY, Barr WH, Eusebio RA, et al. Risedronate pharmacokinetics and intra-and inter-subject variability upon single-dose intravenous and oral administration. Pharm Res. 2001;18:166-170.
18. Marathe PH, Greene DS, Lee JS, et al. Assessment of effect of food, gender, and intra-subject variability in the pharmacokinetics of avitriptan. Biopharm Drug Dispos. 1998;19:153-157.